Stockholm, November 24, 2017 — Nasdaq (Nasdaq: NDAQ) announces that the trading in 2cureX AB’s shares (short name: 2CUREX) commenced today on Nasdaq First North in Stockholm. 2cureX belongs to the healthcare sector and is the 100th company to be admitted to trading on Nasdaq’s Nordic markets* in 2017.
Founded in 2006, 2cureX is a biotech company with a vision to improve treatment efficiency of cancer patients. The company has developed the IndiTreat method, an in-vitro test specialized in identifying and matching the individual cancer patient with the most effective medical treatment. The first IndiTreat product is directed towards colorectal cancer. 2cureX is headquartered in Copenhagen, Denmark. For more information, please visit www.2curex.com.
“We are excited about today’s successful listing on Nasdaq Fist North,” said Ole Thastrup, CEO of 2cureX. “We are looking forward to continuing our journey as a public company.”
“We welcome 2cureX to our European growth market, Nasdaq First North,” said Adam Kostyál, SVP and Head of European listings at Nasdaq. “2curex joins our strong and growing healthcare sector, and we look forward to stand by them on their journey as a public company.”
2cureX AB has appointed Sedermera Fondkommission AB as the Certified Adviser.
*Main markets and Nasdaq First North at Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm.
About Nasdaq First North
Nasdaq First North is regulated as a multilateral trading facility, operated by the different exchanges within Nasdaq Nordic (Nasdaq First North Denmark is regulated as an alternative marketplace). It does not have the legal status as an EU-regulated market. Companies at Nasdaq First North are subject to the rules of Nasdaq First North and not the legal requirements for admission to trading on a regulated market. The risk in such an investment may be higher than on the main market.
Nasdaq (Nasdaq: NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 89 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to 3,800 total listings with a market value of $11 trillion. To learn more, visit: http://business.nasdaq.com
Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland, Nasdaq Riga, Nasdaq Stockholm, Nasdaq Tallinn, Nasdaq Vilnius, Nasdaq Clearing and Nasdaq Broker Services are respectively brand names for the regulated markets of Nasdaq Copenhagen A/S, Nasdaq Helsinki Ltd., Nasdaq Iceland hf., Nasdaq Riga, AS, Nasdaq Stockholm AB, Nasdaq Tallinn AS, AB Nasdaq Vilnius, Nasdaq Clearing AB and Nasdaq Broker Services AB. Nasdaq Nordic represents the common offering by Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm. Nasdaq Baltic represents the common offering by Nasdaq Tallinn, Nasdaq Riga and Nasdaq Vilnius.
Cautionary Note Regarding Forward-Looking Statements
The matters described herein contain forward-looking statements that are made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about Nasdaq and its products and offerings. We caution that these statements are not guarantees of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond Nasdaq's control. These factors include, but are not limited to factors detailed in Nasdaq's annual report on Form 10-K, and periodic reports filed with the U.S. Securities and Exchange Commission. We undertake no obligation to release any revisions to any forward-looking statements.
|Media Relations Contact|
|+46 73 449 78 07|